Patents by Inventor Juping DING

Juping DING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230125233
    Abstract: Provided is a pyrimidine derivative, a preparation method and a use thereof, wherein the pyrimidine derivative is selected from a compound represented by Formula (I), or a tautomer, an enantiomer, a diastereomer, a mesomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt or prodrug thereof. The pyrimidine derivative shows an excellent CDK-inhibiting effect and action.
    Type: Application
    Filed: December 22, 2022
    Publication date: April 27, 2023
    Inventors: Qiang YU, Juping DING, Mulin TANG, Yan HAO, Qin LU, Shen QIAN, Xusheng TIAN
  • Salt of cetagliptin, preparation method thereof, pharmaceutical composition, and use thereof
    Patent number: 11046701
    Abstract: The present invention relates to a salt of a compound of formula (I), The salt is crystalline or amorphous phosphate, or crystalline or amorphous oxalate. Particularly, a crystal form B of the phosphate of the present invention has high crystallinity, low hygroscopicity and good stability, and the crystal form B of the phosphate is good in oral bioavailability, good in tolerance after long-term administration, difficult to induce hypoglycemia and good in inhibition effect on serum DPPIV.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: June 29, 2021
    Assignee: CGENETECH (SUZHOU, CHINA) CO., LTD.
    Inventors: Yan Hao, Renyan Zhang, Huiping Pan, Fuzhi Zhang, Shijie Yin, Juping Ding, Qiang Yu
  • SALT OF CETAGLIPTIN, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION, AND USE THEREOF
    Publication number: 20200123164
    Abstract: The present invention relates to a salt of a compound of formula (I), The salt is crystalline or amorphous phosphate, or crystalline or amorphous oxalate. Particularly, a crystal form B of the phosphate of the present invention has high crystallinity, low hygroscopicity and good stability, and the crystal form B of the phosphate is good in oral bioavailability, good in tolerance after long-term administration, difficult to induce hypoglycemia and good in inhibition effect on serum DPPIV.
    Type: Application
    Filed: May 29, 2018
    Publication date: April 23, 2020
    Applicant: CGENETECH (SUZHOU, CHINA) CO., LTD.
    Inventors: Yan HAO, Renyan ZHANG, Huiping PAN, Fuzhi ZHANG, Shijie YIN, Juping DING, Qiang YU